Huayuan Zhu

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Prognostic Factors

Diffuse Large B Cell Lymphoma

Chronic Lymphocytic Leukemia

Top Venues

Annals of hematology

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

Shuchao Qin, Rui Jiang, Luomengjia Dai, Yi Miao, Yeqin Sha, Tonglu Qiu, Chongyang Ding, Zhen Wang, Chuanbing Shi, Yi Xia, Lei Fan, Wei Xu, Jianyong Li, Huayuan Zhu
Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience. Annals of hematology 103 (5) (2024)
Shuchao Qin, Rui Jiang, Luomengjia Dai, Yi Miao, Yeqin Sha, Tonglu Qiu, Chongyang Ding, Zhen Wang, Chuanbing Shi, Yi Xia, Lei Fan, Wei Xu, Jianyong Li, Huayuan Zhu
Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience. Annals of hematology 103 (5) (2024)
Shuchao Qin, Rui Jiang, Luomengjia Dai, Yi Miao, Yeqin Sha, Tonglu Qiu, Chongyang Ding, Zhen Wang, Chuanbing Shi, Yi Xia, Lei Fan, Wei Xu, Jianyong Li, Huayuan Zhu
Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience. Annals of hematology 103 (5) (2024)
Shuchao Qin, Rui Jiang, Luomengjia Dai, Yi Miao, Yeqin Sha, Tonglu Qiu, Chongyang Ding, Zhen Wang, Chuanbing Shi, Yi Xia, Lei Fan, Wei Xu, Jianyong Li, Huayuan Zhu
Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience. Annals of hematology 103 (5) (2024)
Shuchao Qin, Rui Jiang, Luomengjia Dai, Yi Miao, Yeqin Sha, Tonglu Qiu, Chongyang Ding, Zhen Wang, Chuanbing Shi, Yi Xia, Lei Fan, Wei Xu, Jianyong Li, Huayuan Zhu
Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience. Annals of hematology 103 (5) (2024)
Shuchao Qin, Rui Jiang, Luomengjia Dai, Yi Miao, Yeqin Sha, Tonglu Qiu, Chongyang Ding, Zhen Wang, Chuanbing Shi, Yi Xia, Lei Fan, Wei Xu, Jianyong Li, Huayuan Zhu
Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience. Annals of hematology (2024)
Shuchao Qin, Rui Jiang, Luomengjia Dai, Yi Miao, Yeqin Sha, Tonglu Qiu, Chongyang Ding, Zhen Wang, Chuanbing Shi, Yi Xia, Lei Fan, Wei Xu, Jianyong Li, Huayuan Zhu
Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience. Annals of hematology 103 (5) (2024)
Hailing Liu, Lei Cao, Xiaoli Zhao, Yi Miao, Wei Wu, Xiao Shi, Xiaoyan Zhang, Hua Yin, Huayuan Zhu, Wei Xu, Jianyong Li, Lei Fan
Metronomic chemotherapy for indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Cancer science (2023)
Yi Miao, Yeqin Sha, Yi Xia, Shuchao Qin, Rui Jiang, Luomengjia Dai, Hui Shen, Tonglu Qiu, Wei Wu, Jingyan Qiu, Yilian Yang, Chongyang Ding, Yujie Wu, Lei Fan, Wei Xu, Jian-Yong Li, Huayuan Zhu
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort. Blood cancer journal 13 (1) (2023)